Boule Diagnostics AB has signed a distribution agreement with the American company Medica Corporation Inc., to promote and sell their EasyRA product in the United States.

EasyRA is a system for clinical chemistry used to assist in patient diagnosis and determine problems, related to for example liver, kidney function and high cholesterol levels. The product is cleared for marketing by the FDA, the US Food and Drug Administration. Boule will begin marketing the product in the first quarter 2016.
“The decentralized market for in-vitro diagnostics is expanding in the United States. Cooperation with Medica, through the sale and distribution of their product EasyRA®, means that we can now offer our end customers the combination of hematology and chemistry systems they are looking for. This increases our ability to continue to gain market share in the US market, the world’s largest in-vitro diagnostics market,” says Ernst Westman, President and CEO, Boule Diagnostics AB.
“With the United States well-established brands, Medonic and CDS, Boule is an ideal partner for us. Our products complement each other very well. Furthermore, Boule is well established in the major US distribution channels and their products have a good reputation by their high quality and reliability,” says Robert Hagopian, CEO, Medica Corporation.

Source: Boule Diagnostics